ArticleJournal of neuro-oncology2014
An analysis of radiation necrosis of the central nervous system treated with bevacizumab.
Article in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.BMC cancer · 2021Pooled it
- Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review.Frontiers in oncology · 2021Pooled it
- 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Guideline
- Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.The Cochrane database of systematic reviews · 2018Pooled it
- Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy.Journal of neuro-oncology · 2015Trial
- Bevacizumab: The future of chronic subdural hematoma.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2026Review
- Descriptive Analysis of Surgically Resected Pure Radiation Necrosis After Radiation Therapy for Brain Metastasis: Clinical Features, MRI Findings, and Outcomes.Brain tumor research and treatment · 2026Article
- Incidence of radiation necrosis following different radiotherapy fractionation schedules for intracranial meningiomas.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Remarkable Resolution of Radiation Necrosis Post-Obsessive-Compulsive Disorder Radiosurgery With Boswellia Serrata: Case Report.Advances in radiation oncology · 2025Article
- A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part II-Essential Information on Post-Treatment Imaging.Korean journal of radiology · 2025Review
- The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases.Neuro-oncology · 2024Review
- Adverse radiation effect versus tumor progression following stereotactic radiosurgery for brain metastases: Implications of radiologic uncertainty.Journal of neuro-oncology · 2024Article
- Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series.Cancers · 2023Article
- Distinguishing Brain Metastasis Progression From Radiation Effects After Stereotactic Radiosurgery Using Longitudinal GRASP Dynamic Contrast-Enhanced MRI.Neurosurgery · 2023Article
- Management of initial and recurrent radiation-induced contrast enhancements following radiotherapy for brain metastases: Clinical and radiological impact of bevacizumab and corticosteroids.Clinical and translational radiation oncology · 2023Article
- Bevacizumab is an effective treatment for symptomatic cerebral necrosis after carbon ion therapy for recurrent intracranial malignant tumours: A case report.Molecular and clinical oncology · 2022Article
- Histopathology and surgical outcome of symptomatic treatment-related changes after gamma knife radiosurgery in patients with brain metastases.Scientific reports · 2022Article
- Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.Biomedicines · 2022Review
- Anti-angiogenic therapies in the management of glioblastoma.Chinese clinical oncology · 2021Article
- The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes.Journal of neuro-oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation necrosis is a devastating complication following radiation to the central nervous system. The purpose of this study was to perform a comprehensive analysis of cases in the literature using bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as treatment for radiation necrosis. A MEDLINE/PubMed search of articles about the use of bevacizumab for radionecrosis treatment yielded 16 studies published between 2007 and 2012. Data was summarized according to patient characteristics, treatment received and outcomes measured. A total of 71 unique cases were identified that met the inclusion criteria. The median age at the time of treatment with bevacizumab was 47 years. The most common tumors treated were glioblastoma (31 %), anaplastic glioma (14 %), and metastatic brain tumors (15 %). The median time from ending radiotherapy to starting treatment with bevacizumab was 11 months and the median follow up time after bevacizumab treatment was 8 months. The median number of cycles of bevacizumab was administered was 4, and the median dosage of bevacizumab was 7.5 mg/kg. The median time elapsed between cycles of bevacizumab was 2 weeks. Overall, pre and post treatment imaging revealed a median decrease in T1 contrast enhancement of 63 %, and a 59 % median decrease in T2/FLAIR signal abnormality. Treatment with bevacizumab resulted in a significant radiographic response for patients with radionecrosis. The median dosage of bevacizumab of 7.5 mg/kg for four cycles every 2 weeks should be considered as a treatment option in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.